Reliable handheld XRF results across applications depend on different factors like system setup, sample preparation, accessories, and training.
Analyst rates Kimbell Royalty Partners a Buy at $15.15, citing an 11% normalized yield and a $17.29 target over 12–18 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results